论文部分内容阅读
本文报告了与CCU中静注链激酶相比早期AMI病人在急诊室内静注链酶的可行性、安全性和有利的血液动力学方面的研究。方法:自1986年9月至1987年12月收治的AMI病人64例,收入CCU之前在急诊室予静注链激酶洽疗(ER组);1986年9日以前在CCU中静注链激酶治疗的66例病人做与对照(CCU组).治疗指征①前壁AMI症状出现在4小时内或下壁/后壁心肌梗塞症状出现少于2小时;②ECG有广泛AMI征象(前壁AMISTⅠ、aVL和/或STv_(1-?)抬高>1.2mV或STⅡ.Ⅲ、aVF抬高及心前对应导联ST段下移>0.6mV);③临床和ECG表现不分,而舌下含化硝酸甘油0.5mg有效.禁忌症:年龄在70岁以上;先前曾用链激酶及其他抗纤溶剂治疗;入院前曾心脏按摩;月经期、新近(<6月)的胃肠道出血及脑血管意外。适宜治疗者给静注氢化考的松100mg后静注链激酶150万位位,持续30分钟以上.所有病人均于标准的冠心病监护,在开
This article reports on the feasibility, safety, and beneficial hemodynamic aspects of intravenous streptylase in early-stage AMI patients compared with intravenous streptokinase in CCU. METHODS: Sixty-four AMI patients were enrolled in the AMI from September 1986 to December 1987 and were treated with intravenous streptokinase (ER) in the emergency room before admission to CCU. In the CCU, streptokinase therapy was performed before September 9, 1986 66 cases of patients with the control group (CCU group) .Indication indications ① AMI symptoms in the anterior wall appear within 4 hours or symptoms of inferior wall / posterior wall myocardial infarction appear less than 2 hours; ②ECG has a wide range of AMI signs (anterior wall AMISTⅠ, aVL and / or STv_ (1-?) elevation> 1.2mV or ST.II.III, aVF elevation and pre-cardiac corresponding lead ST segment down> 0.6mV); ③ clinical and ECG performance is not divided, and sublingual Nitroglycerin 0.5 mg is effective Contraindications: Age over 70 years; previously treated with streptokinase and other anti-fibrinolytic agents; cardiac massage prior to admission; menstrual period, recent (<6 months) gastrointestinal bleeding and cerebrovascular accident . Suitable for treatment of intravenous hydrocortisone test of corticosteroids 100mg intravenous streptokinase 1.5 million for 30 minutes or more.All patients in the standard coronary care, in the open